Ask AI

Myelofibrosis: From Disease Biology and Risk Stratification to JAK Inhibitor Selection, Symptom Control, and Individualized Patient Care

This slideset reviews the biology and clinical course of myelofibrosis, including JAK-STAT pathway dysregulation, prognostic risk stratification, symptom and cytopenia burden, and the role of molecular and clinical features in treatment planning. Here, an expert examines pivotal and contemporary evidence supporting the use of JAK inhibitors, including ruxolitinib, pacritinib, momelotinib, and fedratinib, with attention to spleen volume reduction, symptom improvement, hematologic considerations, survival outcomes, and agent selection based on platelet count, anemia, transplant eligibility, and other patient-specific factors. The activity also addresses supportive care, quality-of-life burden, health disparities, and the importance of aligning treatment goals with patient preferences, helping learners apply available evidence to individualized management decisions across the myelofibrosis disease spectrum.

Myelofibrosis Biology to Treatment

Activity Information

Released: August 25, 2026